Clinical Study: Patients with Early Age-Related Macular Degeneration Benefit from Phototrop.NEW ORLEANS New Orleans (ôr`lēənz –lənz, ôrlēnz`), city (2006 pop. 187,525), coextensive with Orleans parish, SE La., between the Mississippi River and Lake Pontchartrain, 107 mi (172 km) by water from the river mouth; founded -- Phototrop(R), a patented dietary supplement Noun 1. dietary supplement - something added to complete a diet or to make up for a dietary deficiency diet - a prescribed selection of foods vitamin pill - a pill containing one or more vitamins; taken as a dietary supplement that combines acetyl acetyl /ac·e·tyl/ (as´e-til) (as´e-tel?) (ah-se´til) the monovalent radical CH3COsbond, a combining form of acetic acid. a·ce·tyl n. L-carnitine, highly concentrated omega-3 and coenzyme Q coenzyme Q n. Ubiquinone. 10, may support and maintain visual function in an elderly patient population at increased risk of developing vision loss. These findings of a double-blind, placebo-controlled study, will be presented today at the 2004 American Academy of Ophthalmology The American Academy of Ophthalmology (AAO) is a medical association of ophthalmologists–medical doctors (MDs) specializing in eye care and surgery). The group is based in San Francisco, California. and European Society of Ophthalmology Joint Meeting in New Orleans. Researchers studied the effect of Phototrop(R) on 106 patients in the early stages of AMD (Advanced Micro Devices, Inc., Sunnyvale, CA, www.amd.com) A major manufacturer of semiconductor devices including x86-compatible CPUs, embedded processors, flash memories, programmable logic devices and networking chips. . The researchers found that the patients experienced a statistically significant decrease in drusen, yellow deposits that accumulate under the retina. As the size and number of drusen increase, central vision can be impaired making it difficult to read or drive. Phototrop(R) was developed by sigma-tau HealthScience, a wholly-owned subsidiary of the Italian pharmaceutical company sigma-tau S.p.A. Phototrop(R) will be available in the United States by the end of the year through the web site: www.phototrop.com. "Our study found a statistically significant decrease in the drusen-covered areas of the eyes of those who were administered Phototrop(R) for a one-year-period, while they increased in those who were taking the placebo," said the study's lead researcher, Dr. Janos Feher, Department of Ophthalmology, University of Rome La Sapienza University of Rome La Sapienza (Italian Università degli Studi di Roma "La Sapienza" . "Phototrop(R) is the only formulation on the market proven to support visual function by facilitating the re-absorption of drusen." There currently are few treatments for older adults suffering from the early stages of degeneration of the macula -- the center of the retina. Advanced AMD is the leading cause of blindness in people 65 and older. Founded in 1957, sigma-tau S.p.A has focused the largest part of its research on the development of metabolic compounds i.e. molecules that occur within the human body. sigma-tau HealthScience was established in 1998 to pursue the development of these compounds in the nutritional supplement area using pharmaceutical-quality standards. For more information, visit www.sigmatau.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion